600518.SH
康美药业
SSE · Healthcare · Medical - Pharmaceuticals · CN
CNY 1.34
−1.47%Aug 25, 2026, 09:09 UTC
Kangmei Pharmaceutical announced its first-half 2026 results: net profit attributable to shareholders was 36.0348 million yuan, up 113.21% year-on-year, while revenue fell 11.13% to 2.29 billion yuan.
Source:Aug 21, 2026, 07:39 UTC
Kangmei Pharmaceutical's chairman Lai Zhijian resigned from his positions as chairman, director, and legal representative, and Ou Guoxiong was appointed to act as chairman and legal representative.
Jul 20, 2026, 08:50 UTC
Kangmei Pharmaceutical received first-instance judgments in two recovery lawsuits, with the court ordering Ma Xingtian, Xu Dongjin, Qiu Xiwei, and Zhengzhong Zhujiang to pay compensation.